Semaglutide

Batch #543209Batch #543209
Report #48250Report #48250
Tested at 6.09mgTested at 6.09mg
Size: 5mg
Visa Mastercard American Express Discover Apple Pay Google Pay
Ships by ...
Flag
FREE Shipping

RESEARCH USE ONLY
These compounds are NOT intended for human consumption, clinical use, or veterinary applications. We are not affiliated with any pharmaceutical companies or their commercial medications. By placing an order, you certify these materials will be used exclusively for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

About Semaglutide

Semaglutide is a synthetic analogue of Glucagon-Like Peptide-1 (GLP-1) a peptide involved in regulating glucose metabolism. It has been studied for its role in influencing insulin secretion and glucagon suppression in a glucose-dependent manner. Research has also explored its potential effects on appetite regulation gastric emptying and intestinal motility as well as its broader implications for metabolic and cardiovascular pathways.

Semaglutide Research

1. Semaglutide and Weight Loss 

This trial examined an injection of semaglutide once a week in overweight and obese adults. During the 68 weeks, people who took semaglutide lost significantly more weight than those who took placebo. 

Semaglutide-treated people lost a little over 15%, on average, of their body weight compared with just over 2.4% for placebo. The findings suggest that semaglutide can lead to significant, sustained weight loss over more than a year.

 

2. Improvements in Cardiometabolic Health 

In addition to weight loss, semaglutide also led to other health improvements. On several measures, like waist circumference, blood pressure and blood sugar levels, people in the treatment group had better outcomes. These gains can lower the risk for type-2 diabetes, heart disease and other metabolic issues.

 

3. Safety & Side Effects  

Most side effects were gastrointestinal (stomach or digestive) symptoms diarrhea, nausea and vomiting. Most cases were mild to moderate. A larger number of people in the semaglutide group discontinued treatment because of side effects compared with the placebo group, but overall safety was deemed to be acceptable in the trial.

 

4. Study Strengths & Limitations

The strength of this study was its large number of participants and time duration, more than one year, which enabled it to obtain strong and valid information. It was also set up as a randomized, double-blind, placebo-controlled trial, the gold standard of clinical research, which reduces bias and helps ensure greater confidence in the findings.

But there were also some drawbacks. The study was largely focused on short-term benefits over 68 weeks, and no long-term effects were studied. Such as whether drug users were more prone to cardiovascular events, cancer or face a higher risk of death over time. In addition, the participants might not adequately reflect all age groups like younger people, older ones, or those with more serious health problems. Semaglutide is available by prescription only, and so real-world outcomes might differ from those seen in the controlled trial population.

  

You ask,
we answer.